Skip to main content

Press releases | September 15, 2020

Fried Frank acted as counsel to Lazard as financial advisor to Gilead Sciences, Inc. in Gilead’s US$21 billion acquisition of Immunomedics. The tender offer is not subject to a financing condition and will be funded through approximately US$15 billion in cash on hand, as well as approximately US$6 billion in newly issued debt.  Immunomedics manufactures next-generation antibody-drug conjugate (ADC) technology. Gilead is a research-based biopharmaceutical company. 

The Fried Frank team was led by corporate partner Philip Richter and included corporate special counsel Roy Tannenbaum and corporate associate Elliot P. Barron.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.